Skip to main content

Advertisement

Table 1 Respondent characteristics

From: Insights on diagnosis and therapeutic decision-making patterns for multiple sclerosis treatment: cross-sectional opinion survey results from Japanese neurologists

Characteristics Overall (n = 205) Sub-group by number of MS patients under care P value
Group 1: 1–3 patients (n = 69) Group 2: 4–9 patients (n = 58) Group 3: ≥10 patients (n = 78)
Age, n (%)
 20s 4 (2.0) 3 (4.3) 0 (0.0) 1 (1.3) 0.197
 30s 65 (31.7) 25 (36.2) 17 (29.3) 23 (29.5)  
 40s 80 (39.0) 25 (36.2) 24 (41.4) 31 (39.7)  
 50s 45 (22.0) 13 (18.8) 13 (22.4) 19 (24.4)  
  ≥ 60s 11 (5.4) 3 (4.3) 4 (6.9) 4 (5.1)  
Number of MS patients under care, mean ± SD, (min–max) 8.78 ± 8.92 (1–50) 2.35 ± 0.78 5.14 ± 1.03 17.17 ± 9.54 < 0.001*
Approximate percentages of patients with MS under care, mean ± SD, (min–max) 6.56 ± 7.64 (1–60) 3.14 ± 2.63 (1–10) 5.41 ± 7.41 (1–50) 10.44 ± 9.01 (1–60) < 0.001*
Years of post-residency treatment experience with MS, n (%)
  < 3 years 8 (3.9) 4 (5.8) 2 (3.4) 2 (2.6) 0.009
 3–5 years 16 (7.8) 9 (13.0) 2 (3.4) 5 (6.4)  
 6–10 years 37 (18.0) 14 (20.3) 12 (20.7) 11 (14.1)  
 11–15 years 51 (24.9) 18 (26.1) 14 (24.1) 19 (24.4)  
 16–20 years 40 (19.5) 11 (15.9) 14 (24.1) 15 (19.2)  
  > 20 years 53 (25.9) 13 (18.8) 14 (24.1) 26 (33.3)  
Affiliation, n (%)      
 University hospitals 60 (29.3) 19 (27.5) 8 (13.8) 33 (42.3) 0.019
 National/public hospitals 58 (28.3) 18 (26.1) 20 (34.5) 20 (25.6)  
 Hospitals in general 79 (38.5) 28 (40.6) 27 (46.6) 24 (30.8)  
 Private practice 8 (3.9) 4 (5.8) 3 (5.2) 1 (1.3)  
Membership in professional association, n (%)
 Japanese Society of Neurology 204 (99.5) 68 (98.6) 58 (100.0) 78 (100.0) 0.217
 Japanese Society for Neuroimmunology 36 (17.6) 10 (14.5) 7 (12.1) 19 (24.4) 0.108
 Japanese Society of Neurological Therapeutics 87 (42.4) 18 (26.1) 27 (46.6) 42 (53.8) 0.001
DMDs that had been prescribed in practice, n (%)
 SC IFNβ-1b 199 (97.1) 63 (91.3) 58 (100.0) 78 (100.0) 0.002
 IM IFNβ-1a 180 (87.8) 60 (87.0) 47 (81.0) 73 (93.6) 0.199
 Fingolimod 171 (83.4) 50 (72.5) 47 (81.0) 74 (94.9) < 0.001
 Natalizumab 32 (15.6) 8 (11.6) 3 (5.2) 21 (26.9) 0.009
 Glatiramer acetate 36 (17.6) 13 (18.8) 6 (10.3) 17 (21.8) 0.600
 Other 5 (2.4) 2 (2.9) 1 (1.7) 2 (2.6) 0.907
  1. MS multiple sclerosis, SD standard deviation, min minimum, max maximum, DMD disease-modifying drug, SC IFNβ-1b subcutaneous interferon beta-1b, IM IFNβ-1a intramuscular interferon beta-1a
  2. Percentages do not sum up to 100% due to multiple responses
  3. Percentages were compared between the groups: no mark indicates P values for chi-square tests, and an asterisk (*) indicates P values for one-way ANOVA